296 related articles for article (PubMed ID: 27749242)
1. Effects of rituximab in connective tissue disorders related interstitial lung disease.
Lepri G; Avouac J; Airò P; Anguita Santos F; Bellando-Randone S; Blagojevic J; Garcia Hernàndez F; Gonzalez Nieto JA; Guiducci S; Jordan S; Limaye V; Maurer B; Selva-O'Callaghan A; Riccieri V; Distler O; Matucci-Cerinic M; Allanore Y
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):181-185. PubMed ID: 27749242
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease.
Chartrand S; Swigris JJ; Peykova L; Fischer A
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Jan; 32(4):296-304. PubMed ID: 26847096
[TBL] [Abstract][Full Text] [Related]
3. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.
Saunders P; Tsipouri V; Keir GJ; Ashby D; Flather MD; Parfrey H; Babalis D; Renzoni EA; Denton CP; Wells AU; Maher TM
Trials; 2017 Jun; 18(1):275. PubMed ID: 28619061
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Rituximab in Connective Tissue Disease related Interstitial Lung Disease.
Fitzgerald DB; Moloney F; Twomey M; O'Connell JO; Cronin O; Harty L; Harney S; Henry MT
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):215-21. PubMed ID: 26422566
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in connective tissue disease-associated interstitial lung disease.
Duarte AC; Cordeiro A; Fernandes BM; Bernardes M; Martins P; Cordeiro I; Santiago T; Seixas MI; Ribeiro AR; Santos MJ
Clin Rheumatol; 2019 Jul; 38(7):2001-2009. PubMed ID: 31016581
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary involvement in long-term mixed connective tissue disease: functional trends and image findings after 10 years.
Kawano-Dourado L; Baldi BG; Kay FU; Dias OM; Gripp TE; Gomes PS; Fuller R; Caleiro MT; Kairalla RA; Carvalho CR
Clin Exp Rheumatol; 2015; 33(2):234-40. PubMed ID: 25896472
[TBL] [Abstract][Full Text] [Related]
7. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease.
Moore OA; Proudman SM; Goh N; Corte TJ; Rouse H; Hennessy O; Morrisroe K; Thakkar V; Sahhar J; Roddy J; Youssef P; Gabbay E; Nash P; Zochling J; Stevens W; Nikpour M
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S111-6. PubMed ID: 26243401
[TBL] [Abstract][Full Text] [Related]
8. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
[TBL] [Abstract][Full Text] [Related]
10. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis.
Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Paliogianni F; Sirinian C; Yiannopoulos G; Andonopoulos AP
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S17-22. PubMed ID: 22244622
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.
Fischer A; Brown KK; Du Bois RM; Frankel SK; Cosgrove GP; Fernandez-Perez ER; Huie TJ; Krishnamoorthy M; Meehan RT; Olson AL; Solomon JJ; Swigris JJ
J Rheumatol; 2013 May; 40(5):640-6. PubMed ID: 23457378
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
Fraticelli P; Fischetti C; Salaffi F; Carotti M; Mattioli M; Pomponio G; Gabrielli A
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
[TBL] [Abstract][Full Text] [Related]
13. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
14. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy.
Keir GJ; Maher TM; Hansell DM; Denton CP; Ong VH; Singh S; Wells AU; Renzoni EA
Eur Respir J; 2012 Sep; 40(3):641-8. PubMed ID: 22282550
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease.
Sharp C; McCabe M; Dodds N; Edey A; Mayers L; Adamali H; Millar AB; Gunawardena H
Rheumatology (Oxford); 2016 Jul; 55(7):1318-24. PubMed ID: 27060110
[TBL] [Abstract][Full Text] [Related]
16. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
Owen C; Ngian GS; Elford K; Moore O; Stevens W; Nikpour M; Rabusa C; Proudman S; Roddy J; Zochling J; Hill C; Sturgess A; Tymms K; Youssef P; Sahhar J
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):170-176. PubMed ID: 27049330
[TBL] [Abstract][Full Text] [Related]
17. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.
Maher TM; Tudor VA; Saunders P; Gibbons MA; Fletcher SV; Denton CP; Hoyles RK; Parfrey H; Renzoni EA; Kokosi M; Wells AU; Ashby D; Szigeti M; Molyneaux PL;
Lancet Respir Med; 2023 Jan; 11(1):45-54. PubMed ID: 36375479
[TBL] [Abstract][Full Text] [Related]
18. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease.
Le Gouellec N; Duhamel A; Perez T; Hachulla AL; Sobanski V; Faivre JB; Morell-Dubois S; Lambert M; Hatron PY; Hachulla E; Béhal H; Matran R; Launay D; Remy-Jardin M
PLoS One; 2017; 12(8):e0181692. PubMed ID: 28763468
[TBL] [Abstract][Full Text] [Related]
19. Effects of cyclophosphamide and rituximab in patients with connective tissue diseases with severe interstitial lung disease.
Benad M; Koschel D; Herrmann K; Wiefel K; Kleymann A; Aringer M
Clin Exp Rheumatol; 2022 Mar; 40(3):483-488. PubMed ID: 33635231
[TBL] [Abstract][Full Text] [Related]
20. Rituximab treatment for systemic sclerosis-associated interstitial lung disease: a case series of 13 patients.
Morgan K; Woollard C; Beinart D; Host LV; Roddy J
Intern Med J; 2023 Jul; 53(7):1147-1153. PubMed ID: 35670218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
